Table 1 Correlation of PD-L1 immune high and immune low with clinical, pathologic and molecular features in colon carcinomas not treated with neoadjuvant therapy.
From: Programmed death-ligand 1 expression in the immune compartment of colon carcinoma
PD-L1 immune low (n = 447) | PD-L1 immune high (n = 592) | p- value | |
|---|---|---|---|
Mean age | 67 | 68.5 | 0.11 |
Female | 227/447 (50.8%) | 307/592 (51.9%) | 0.73 |
Right | 214 (51%) | 298 (52.3%) | 0.80 |
Left | 192 (45.7%) | 250 (43.9%) | |
Transverse | 14 (3.3%) | 22 (3.9%) | |
AJCC Stage 1/2/3/4 | 57 (12.8%) | 139 (23.6) | 0.0001 |
160 (36%) | 197 (33.5%) | ||
171 (38.4%) | 200 (34%) | ||
57 (12.8) | 52 (8.8%) | ||
EMVI positive | 172/447 (38.5%) | 174/592 (29.4%) | 0.002 |
PNI positive | 147/446 (33%) | 166/593 (28%) | 0.087 |
Tumor border configuration Pushing (vs. infiltrating) | 121/440 (27.5%) | 214/582 (36.8%) | 0.002 |
BRAF positive | 49/390 (12.6%) | 91/472 (19.3%) | 0.0009 |
MSI dMMR | 66/411 (16.1%) | 118/507 (23.3%) | 0.007 |
